Senti Biosciences (NASDAQ:SNTI - Get Free Report)'s stock had its "buy" rating restated by research analysts at Chardan Capital in a report released on Friday,Benzinga reports. They currently have a $12.00 target price on the stock. Chardan Capital's price objective indicates a potential upside of 277.95% from the stock's current price.
Senti Biosciences Price Performance
Shares of SNTI stock traded down $0.13 during trading hours on Friday, reaching $3.18. The company had a trading volume of 16,857 shares, compared to its average volume of 798,226. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The company has a 50 day moving average of $3.46 and a 200 day moving average of $3.66. The firm has a market cap of $82.78 million, a price-to-earnings ratio of -0.21 and a beta of 2.31.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.30 million. As a group, sell-side analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Senti Biosciences stock. Virtu Financial LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,356 shares of the company's stock, valued at approximately $47,000. Virtu Financial LLC owned about 0.28% of Senti Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 25.73% of the company's stock.
Senti Biosciences Company Profile
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Featured Articles
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
